Top Section/Ad
Top Section/Ad
Most recent
French biotech seeks to accelerate cancer vaccine program
Payment processor's shares dropped to new low on Thursday
More articles/Ad
More articles/Ad
More articles
-
Equity capital markets have been relentless since the first coronavirus rescue issues in the spring. There is no let-up, with several large deals announced in the past fortnight and scheduled to be priced in August. However, bankers are worried that tired investors are near breaking point. -
The UK government’s decision over the weekend to reintroduce a quarantine on travellers from Spain is set to make a rights issue far more difficult for International Consolidated Airlines Group (IAG), the airline holding company which owns British Airways, according to equity capital markets sources.
-
EMEA’s equity capital markets were buzzing on Friday morning after Goldman Sachs placed a 13.2m block of shares in Cellnex, the Spanish telecoms tower company, which allowed the company’s largest shareholder to monetise rights that it intends not to exercise in the issuer's forthcoming €4bn rights issue.
-
Indian private sector lender Axis Bank has lined up four European banks for an equity sale that could raise up to Rp150bn ($2bn), according to a source close to the deal.
-
BioNTech, the German biopharmaceuticals company, is selling 5.5m American Depositary Receipts (ADRs) on the Nasdaq through a share sale and a rights issue. The company, which is working with Pfizer to develop a vaccine for Covid-19, is the latest issuer to hit the market in a wave of biotech ECM issuance — but buyers are being warned against being too eager, reports Sam Kerr.
-
Cellnex, the Spanish telecommunications towers operator, has launched a €4bn underwritten rights issue to fund acquisitions.
